Sign In
Buy NVS
$153.38
+4.45 (+2.99%)
At Close: Jun 23, 2026
Novartis (NVS) Set to Advance Malaria Drug Into Phase III
12:02pm, Thursday, 24'th Nov 2022
Novartis (NVS) plans to advance ganaplacide/lumefantrine into a phase III study for the treatment of patients with acute uncomplicated malaria due to Plasmodium falciparum.
3 Biotech Stocks Smart Investors Should Be Buying Up Now
01:51am, Thursday, 24'th Nov 2022
For investors looking for growth, biotech stocks are a great place to start one's search. This is a sector that's seen its valuation multiples decline in many cases to a greater extent than the overa
2 Top Biotech Stocks to Buy Right Now
02:45pm, Saturday, 19'th Nov 2022 The Motley Fool
These two rank among the 10 largest pharmaceutical companies on the planet.
2 Top Biotech Stocks to Buy Right Now
09:45am, Saturday, 19'th Nov 2022
These two rank among the 10 largest pharmaceutical companies on the planet.
Novartis (NVS) Reportedly Looking to Sell Its Business Units
03:01pm, Thursday, 17'th Nov 2022 Zacks Investment Research
Per a Bloomberg report, Novartis (NVS) is considering the sale of its ophthalmology and respiratory franchises.
Ionis (IONS) Inks Deal to Develop Precision Genetic Medicines
05:19pm, Tuesday, 15'th Nov 2022 Zacks Investment Research
Ionis (IONS) inks collaboration deal with the gene editing company, Metagenomi, to expand the former's capabilities in delivering precision genetic medicines.
Novartis: Limited Growth
04:43pm, Tuesday, 15'th Nov 2022
We analyzed the latest Pharma conference with key takeaways on the Inflation Reduction Act development and the company's reorganization. Limited growth potential with no current positive catalyst.
Should Income Investors Buy This High-Yielding Dividend Stock?
02:15pm, Sunday, 13'th Nov 2022 The Motley Fool
Novartis' product portfolio and pipeline bode well for its future.
Should Income Investors Buy This High-Yielding Dividend Stock?
09:15am, Sunday, 13'th Nov 2022
Novartis' product portfolio and pipeline bode well for its future.
Emergent's (EBS) Q3 Earnings and Revenues Miss Estimates
03:47pm, Wednesday, 09'th Nov 2022 Zacks Investment Research
Emergent's (EBS) third-quarter 2022 earnings and revenues miss estimates. EBS issues fresh guidance for its CDMO services
ImmunoGen (IMGN) Q3 Loss Wider, Sales Beat, '22 View Up
07:07pm, Monday, 07'th Nov 2022 Zacks Investment Research
ImmunoGen (IMGN) reports a wider-than-expected loss in third-quarter 2022. Nevertheless, it beat revenue estimates. The company raises its financial guidance for 2022
2 Biotech Stocks That Could Make You Richer
01:07pm, Friday, 04'th Nov 2022 The Motley Fool
Both drugmakers are pretty close to their 52-week highs, but that shouldn't stop investors.
Pharma Stock Roundup: NVS, MRK Report Q3 Earnings JNJ's Tecvayli Gets FDA Nod
04:09pm, Friday, 28'th Oct 2022 Zacks Investment Research
Novartis (NVS) and Merck (MRK) announce Q3 results. FDA approves J&J's (JNJ) multiple myeloma candidate, Tecvayli.
Alnylam's (ALNY) Earnings and Revenues Lag Estimates in Q3
03:00pm, Thursday, 27'th Oct 2022 Zacks Investment Research
Alnylam's (ALNY) earnings and sales fall shy of estimates in the third quarter of 2022. The company maintains its product revenue guidance for 2022.
3 High-Yielding Dividend Stocks That You Can Buy and Hold Forever
01:15pm, Thursday, 27'th Oct 2022 The Motley Fool
These stocks are all trading close to their 52-week lows.
